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Background: In clinical and basic research custom panels for transcript profiling are gaining importance because
only project specific informative genes are interrogated. This approach reduces costs and complexity of data analysis
and allows multiplexing of samples. Polymerase-chain-reaction (PCR) based TaqMan assays have high sensitivity but
suffer from a limited dynamic range and sample throughput. Hence, there is a gap for a technology able to measure
expression of large gene sets in multiple samples.
Results: We have adapted a commercially available mRNA quantification assay (AmpliSeq-RNA) that measures mRNA
abundance based on the frequency of PCR amplicons determined by high-throughput semiconductor sequencing.
This approach allows for parallel, accurate quantification of about 1000 transcripts in multiple samples covering a
dynamic range of five orders of magnitude. Using samples derived from a well-characterized stem cell differentiation
model, we obtained a good correlation (r = 0.78) of transcript levels measured by AmpliSeq-RNA and DNA-microarrays.
A significant portion of low abundant transcripts escapes detection by microarrays due to limited sensitivity. Standard
quantitative RNA sequencing of the same samples confirms expression of low abundant genes with an overall
correlation coefficient of r = 0.87. Based on digital AmpliSeq-RNA imaging we show switches of signaling cascades at
four time points during differentiation of stem cells into cardiomyocytes.
Conclusions: The AmpliSeq-RNA technology adapted to high-throughput semiconductor sequencing allows robust
transcript quantification based on amplicon frequency. Multiplexing of at least 900 parallel PCR reactions is feasible
because sequencing-based quantification eliminates artefacts coming from off-target amplification. Using this
approach, RNA quantification and detection of genetic variations can be performed in the same experiment.
Keywords: Semiconductor RNA sequencing, Digital transcript imaging, Multiplex analysisBackground
Personal healthcare has the goal to deliver specific targeted
therapeutics to patient groups stratified based on pre-
dictive genetic or transcriptional markers. The availability
of several hundred complete human genomes in the
public domain has added a high degree of confidence
to genetic markers predicting susceptibility to certain
disorders. Robust and validated PCR-based assays interro-
gating disease specific single-nucleotide-polymorphisms
(SNP) panels are routinely used in exploratory and clinical
research using formalin fixed-paraffin embedded (FFPE)
or biopsy derived DNA samples. The de novo discovery of
dynamic mRNA biomarkers that inform about drug* Correspondence: ulrich.certa@roche.com
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unless otherwise stated.response or specific gene expression patterns is regularly
done by genome-wide transcript profiling using DNA
microarrays or quantitative RNA sequencing. However,
both technologies require relatively high amounts of
high quality RNA complicating genome-wide transcript
profiling of clinical samples.
For translational research novel primary cell based tissue
models are emerging. Induced pluripotent stem cell (iPSC)
technology allows in vitro generation of tissue specific
human cells such as cardiomyocytes. In addition, spher-
ocyte based three-dimensional culture systems allow
small-scale engineering of human tissues containing cell
types present in the native tissue. In contrast to patient
derived tissues these in vitro models can be exposed to
drugs at various dose-levels and multiple time-points in
a well-controlled laboratory environment. The mainLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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analysis of drug-responses using a variety of dynamic
parameters such as transcript levels. Differentially expressed
transcripts found in 3D-cultures, human primary cells
or clinical samples are useful resources for generation
of customized assays interrogating expression of disease
relevant genes only. The microfluidics based quantitative
PCR (qPCR) platform (“Fluidigm”) allows multiparallel
expression analysis of 96 custom transcripts in 96 samples
at high sensitivity with low RNA input [1]. The Luminex
system is a multiplexed color-coded microsphere-based
suspension platform for digital quantification of up to 100
custom transcripts in a single tube [2]. The Nanostring
technology uses complementary probes coupled with large
color-coded DNA molecules to label transcripts followed
by confocal microscope-based digital quantification at
single molecule sensitivity [3]. Alternatively, oligonucleotide
probe coated cantilever arrays have been used to quantify
transcripts in cell lysates based on nano-mechanical bend-
ing [4]. The production of custom microarrays was
discontinued by most suppliers due to high costs and
declining market size. For routine applications, qPCR
profiling (Taqman assay) is the method of choice because it
is performed in conventional 96-well plates using standard
thermocyclers [5]. In addition, custom gene qPCR panels
covering various major biological processes such as
apoptosis, cell cycle control or immune stimulation are
commercially available from a number of vendors. All
technologies briefly outlined above suffer either from
low sample throughput or else from a rather limited
number of transcripts for multiparallel analysis.
Recently a combination of PCR amplification and semi-
conductor sequencing termed AmpliSeq became com-
mercially available for customized detection of sequence
based single-nucleotide polymorphisms (SNPs) or point
mutations [6]. Compared to standard PCR assays this
technology provides the sequence flanking the mutation
of interest at high coverage permitting quantitative
determination of allele frequencies. For cancer research
for instance, a commercial panel of 190 primer pairs
covering hot-spot mutations in 46 cancer-related genes
is available for low-throughput semiconductor sequencers
[7,8]. This gene panel was used in a pilot study for
AmpliSeq validation using clinical (FFPE) lung cancer
samples [9-11]. The amplicon size of 80 to 100 base
pairs is compatible with partially degraded material
which is very challenging to sequence by classical DNA
sequencing methods such as Sanger-sequencing. All
clinical FFPE samples were successfully amplified and
sequenced with 10ng DNA input. The allele frequencies
determined by Sanger-sequencing were confirmed by
AmpliSeq technology [12]. Therefore it is likely that
focused parallel sequencing will gain attention in clin-
ical studies and for patient stratification.Here we present the first AmpliSeq-based RNA quan-
tification (AmpliSeq-RNA) in multiple samples using a
custom panel of 917 individual amplicons quantified
by high-throughput Ion-Torrent-Proton semiconductor
sequencing [13]. For validation, we have chosen RNA
samples derived from four time points of a published
cardiomyocyte differentiation experiment as a well-
characterized biological system [14]. Expression values
measured by AmpliSeq-RNA data correlate well with
equivalent microarray data or conventional quantitative
RNA sequencing. Adaptation of AmpliSeq-RNA technol-
ogy to high-performance semiconductor technology closes
an important gap in custom RNA analysis because it
allows for the first time multi-parallel expression analysis
of hundreds of genes in up to one hundred samples
covering a dynamic range of five orders of magnitude.
Results
Workflow of AmpliSeq-based digital transcript imaging
(AmpliSeq-RNA)
Compared with DNA genotyping, the AmpliSeq-RNA
quantification workflow (Figure 1) requires polyA-primed
conversion of mRNA to cDNA followed by target specific
PCR amplification using a multiplex primer pool. Each
primer pair amplifies a unique 80-100 base pair cDNA
fragment using a limited number of PCR cycles important
for maintenance of transcript stoichiometry. After amp-
lification a DNA-barcode is attached to each sample
followed by pooling and emulsion-PCR of all samples.
Following bead library construction the amplicon library
is sequenced on an Ion-Torrent Proton instrument.
Decoding of samples and quantitative mapping to the
input amplicon sequences concludes the experimental
workflow. For experimental validation of AmpliSeq-RNA
we have compiled a custom panel of 917 transcripts
representing about 150 biological signaling cascades.
This gene set was collected from commercial pathway
panels, public domain resources such as Pathway Commons
(www.pathwaycommons.org) or relevant literature [Zhang,
J.D., manuscript in preparation]. We anticipated that this
pathway-based transcript panel would report major vari-
ances in gene expression programs across very diverse
cell-types. Therefore we considered the differentiation
of inducible pluri-potent stem cells (iPSC) into cardio-
myocytes as an appropriate test case [14].
In addition, we adapted the AmpliSeq-RNA technology
to the high-throughput Ion-Torrent Proton semiconductor
sequencer which generates about 100-times more reads
than the Personal Genome Sequencer (PGM) originally
used. This expansion of capacity allows adaptation to the
experimental needs by either adjusting the dynamic range
or the number of samples. In the current study, the pooled
samples coming from biological triplicates of four time-
points (day 0, day, 10, day 20, day 60) were sequenced
Figure 1 Experimental workflow for AmpliSeq-RNA based
transcript quantification. An aliquot of the custom primer pool, the
cDNA sample and a PCR master-cocktail are combined in individual
tubes or multititer plate wells. Following pre-amplification the amplicons
are tagged with a sample specific molecular barcode followed by
pooling and emulsion PCR (ePCR) amplification on nanosphere-beads.
After semiconductor sequencing (Ion-Torrent-Proton) reads are mapped
to the target sequence library. Read frequencies proportional to transcript
abundance are provided in a standard spread-sheet for further analysis
(for experimental details see Methods Section).
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16’362’403, 11’145’049, 15’951’406 and 12’467’509 mapped
reads for day 0, day 10, day 20 and day 60 respectively.
The most abundant amplicons of our panel are repre-
sented by up to 800’000 reads exceeding the needs of most
profiling experiments. We have set the lower detection
limit to an average of five reads per amplicon in order to
reduce artefacts known as the “Monte Carlo effect” caused
by stochastic single molecule amplification at low input
RNA levels [15].Technical and biological validation of AmpliSeq-RNA
To keep this technology-focused study in a manageable
scope we selected triplicate RNA samples from day 0,
10, 20 and 60 of our published iPSC differentiation
experiment for AmpliSeq-RNA validation. To confirm
integrity of the reference samples we have repeated the
published microarray profiling analysis [14]. Prior to
the biological evaluation we assessed technical variation
of the AmpliSeq-RNA technology adapted to Proton-
sequencing. We selected a single RNA sample (day 60)
and prepared four independent sequencing libraries using
25 nanogram input RNA per technical replicate. Following
sequencing and transcript quantification we calculated a
common coefficient of variation of 0.16 (defined as sigma/
mean) for AmpliSeq-RNA. The observed inter-sample
variation is in the range of established RNA profiling
technologies such as qPCR (1% ~ 15%; [16,17]) micro-
array (5% ~ 15%; [18]) or quantitative RNA sequencing
(10% ~ 15%; [19]).
Comparison of AmpliSeq-RNA gene expression with
microarrays and quantitative RNA-sequencing
Next we compared the read-frequencies measured by
AmpliSeq-RNA with equivalent data from Illumina micro-
rarrays [20] or from quantitative RNA sequencing [21] at
day 0, 10, 20 and 60 (Figure 2). We selected an average
amplicon length of about 100 nucleotides matching the
median read length of the Ion-Torrent Proton sequencing
technology. As a result, the number of reads per amplicon
is directly proportional to transcript abundance circum-
venting the need for data normalization. In contrast, results
obtained by conventional quantitative RNA sequencing
require length normalization and are expressed as RPKM
(reads per kilo base per million reads) values. In addition,
uneven read coverage along a given transcript can compli-
cate precise quantification. Fluorescence-based microarray
technology suffers from low sensitivity as result of back-
ground noise. Nevertheless, we included this technology
for benchmarking with published data. Above the noise
level of 8 on log2 scale we found an almost linear relation
of AmpliSeq-RNA and microarray data at a confidence
level of 95% across all time points. Genes below this
noise level are not detected resulting in a sigmoid curve
(Figure 2A). The correlation coefficient of 0.77 for Ampli-
Seq –RNA and microarrays is similar to the correlation
of r = 0.73 found in a comparison between microarrays
and conventional, quantitative RNA-sequencing [19].
To confirm expression of all transcripts detected by
AmpliSeq-RNA we profiled the same samples by conven-
tional strand-specific RNA sequencing as an independent
technology with comparable sensitivity. We obtained a
nearly linear relation between the two datasets with an
average correlation coefficient of r ≈ 0.87 for all time
points (Figure 2B).
Figure 2 Comparison of RNA- profiling to microarrays and quantitative RNA sequencing. (A) Correlation of gene expression profiles generated
by AmpliSeq-RNA (y-axis) and DNA microarrays (x-axis) using identical RNA samples. Each circle corresponds to one gene of our custom gene panel
measured on both platforms. Curves in red indicate the local regression (LOESS) fit between the two profiles, and shades in red give 95% confidence
interval of the fitting. The grey vertical line indicates the detection limit of microarrays and horizontal line the arbitrary detection limit of less than one
read per sample. (B) Gene expression profiles of the same samples probed by AmpliSeq-RNA (y-axis) and by conventional quantitative RNA sequencing
(x-axis). Curves and shades in red, like in (A), give the LOESS fit and 95% confidence interval of the fitting. Horizontal and vertical dash lines indicate
the detection limit and transcripts below one count per gene are considered as being absent. Time points of each panel are indicated in the top bar
and the correlation coefficient is displayed in the top left corner of each diagram.
Figure 3 Comparison of linear gene expression changes of
differential called by AmpliSeq-RNA (y-axis) and by microarray
(x-axis). Each dot corresponds to a gene with an absolute log
fold-change larger than one and a p-value smaller than 0.05 using
data from all time points. Yellow dots with a red outline correspond
to genes (n = 237) for which significant differential gene expression
changes are only captured by AmpliSeq-RNA. Color codes corresponding
to microarray (MA) log2 expression levels are shown in the legend insert.
Note that DEGs with moderate to high expression are captured by both
technologies with comparable change factors.
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tional medicine or biomedical research the ability to
measure dynamic transcriptional responses to stimuli is
often more relevant than the determination of absolute
expression values. We addressed this point by comparing
detection of differential gene expression by AmpliSeq-RNA
and microarrays. We selected differentially expressed genes
(DEGs) from all time-points with an absolute log fold-
change larger than one and a p-value smaller than 0.05
(Figure 3). Less abundant DEGs (n = 237) fulfilling the filter
criteria above are only reported by AmpliSeq-RNA thereby
extending the scope of the analysis.
Biological significance of AmpliSeq-RNA data
Despite single molecule sensitivity of deep sequencing, a
specific set of about 50 genes is undetected at each time
point (Table 1). Five genes with preferential expression
in neuronal tissues are absent in all time-points. This
finding shows indirectly that absent calls are related to
lack of gene expression rather than to technical issues.
Transcripts of the FOXA signaling network for instance
are not detected in iPSCs. The forkhead-box-domain
transcriptional regulator family has about forty functionally
distinct member genes and plays pivotal roles in mamma-
lian development [22]. Apart from being a physiological
master regulator, FOXA1 is a potent stimulator of cell pro-
liferation in tumors [23,24]. Likewise, transcripts activated
by the mitogen-activated protein (MAP) kinase signaling
network are not detectable in iPSCs cells. MAP-kinase sig-
naling has pleiotropic functions controlling inflammation,
Table 1 Specificity of AmpliSeq-RNA: Number of






The numbers refer to undetected genes in the entire panel of 917 transcripts.
5 transcripts are absent considering all time points.
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senescence or tumorigenesis in specific cell types [25].
Suppression of FOXA and MAP-kinase signaling is prob-
ably crucial for maintenance of stem cell pluripotency
and homeostasis. Once cardiomyocyte differentiation is
completed genes belonging to the RAS- and JNK- signaling
cascades are suppressed. The RAS pathway is an important
regulator of cell differentiation and a point of convergence
for multiple signaling cascades [26]. Janus kinase signaling
is expected to induce further cell proliferation and apop-
tosis [27]. Suppression of the signal transduction by the
pathways briefly described is consistent with biological
function suggesting faithful performance of AmpliSeq-RNA
transcript imaging.
In order to detect transcriptional re-programming during
differentiation, we chose three master regulator networks
involved in eukaryotic development. The NOS-signaling
pathway has protective properties such as detoxification
and is regulated by nitric oxide the only gas activator of
eukaryotic development [24] . The family of nitric oxide
synthases catalyzes production of protective nitric oxide
from L-arginine following signal transduction to down-
stream pathways. The WNT and stem signaling cascades
are functionally closely related and regulate several
aspects of development including organogenesis, mid-
brain development as well as stem cell proliferation
[28]. WNT signals control cell fate determination, cell
movement and tissue polarity. Loss-of-function muta-
tions and epigenetic silencing in WNT signaling genes
occurs in a variety of human cancers. Notch and the
fibroblast and transforming growth factor receptors are
key regulators of the morphogenetic stem cell signaling
network. This pathway is implicated in the maintenance
of tissue homeostasis by regulating self-renewal of normal
stem cells as well as proliferation and differentiation of
progenitor cells. To demonstrate developmental modula-
tion of these pathways we monitored specific sets of about
25 transcripts for each of them. For NOS, WNT and stem
cell signaling essentially all member genes were found to
be differentially expressed during differentiation (Figure 4).
Regardless of the pathway, all genes with high expression
in stem cells are repressed in the terminal cardiomyocyte
stage and vice versa. Four WNT genes present in ourpanel are only expressed in the transition phase at day
10 and 20 reflecting the role of WNT-proteins in tissue
differentiation and cytoskeleton plasticity. We conclude
that differential gene expression measured by AmpliSeq-
RNA data matches results obtained from genome-wide
transcript profiling.
Discussion and conclusions
The current trend to study subsets of genes rather than
genome-wide gene expression requires appropriate tech-
nologies. Apart from significant cost-reduction, data
interpretation is less complicated and more conclusive due
to focus on relevant data points. The current version of
the microfluidics based Fluidigm technology [1] measures
expression of 96 custom genes in 96 samples by qPCR.
Despite high sensitivity, throughput and dynamic range
are suboptimal. In addition, a significant hardware invest-
ment is involved. Standard quantitative RNA sequencing
comes with single molecule sensitivity and a dynamic
range of at least five orders of magnitude depending on
instrument platform and multiplexing. High-throughput
sample processing is currently restricted by the largely
manual workflow of most platforms, expenses and lav-
ish data processing. We argue that AmpliSeq-RNA can
potentially close these gaps. We demonstrate parallel
amplification of 917 transcripts in a single tube with
comparable efficiency which we consider sufficient for
most biological and medical research applications. We
performed parallel sequencing of 12 barcoded samples to
explore the full dynamic range of the Proton-technology
delivering about 12 million reads per sample under optimal
conditions. For most applications, a profile based on
1 million reads per sample is sufficient for discovery
of significant biological processes. Such a high-level
analysis allows multiparallel analysis of up to 150 samples
in a single run. The short three-hour run time of Proton
sequencers permits completion of two experiments per
day within normal working hours. The low amount of
input RNA ranging from 500 picogram to 5 nanogram
allows analysis of biopsy derived tissue samples and the
small amplicon size of 100 base pairs is compatible with
partially degraded FFPE-tissue [12]. The steadily increas-
ing acceptance of human primary- or iPSC derived three-
dimensional in vitro tissue models as surrogate for clinical
responses is another area where only small amounts of
RNA are available from spheroid body cultures. Apart
from multiplexing options with respect to sample num-
ber and analysis content, we consider sequence based
quantification as an important feature of AmpliSeq-RNA.
Pooling of up to 1’000 primer pairs will likely result in
off-target amplification which cannot be detected by
fluorescence based detection methods. In fact, we found
experimentally that about 3% of all reads do not map to
the amplicon sequence pool probably due to unspecific
Figure 4 Expression patterns of selected genes involved signaling pathways for cell plasticity, growth and differentiation: (A) nitric
oxide signaling (NOS) pathway (28 genes); (B) WNT pathway (23 genes); (C) stem cell signaling (27 genes). Relative transcript abundance
normalized per gene across four time points are visualized with ‘cascade plots’. The order of genes from top to bottom was generated according to
expression at each time point. The diagrams were scaled to the same size. Transcript abundance is color coded from low (red) to high (yellow).
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RNA sequencing that employs genomic read mapping,
AmpliSeq-RNA considers only reads matching the
correct target sequence for quantification resulting in
elimination of off-target born amplicons. Defining the
number of mismatches in the sequences used for mapping
allows detection of genetic variations such as single-
nucleotide polymorphisms (SNPs) and point mutations
in the transcript provided the amplicon covers such
polymorphic stretches. Along the same lines, targeting
of conserved sequence stretches flanking polymorphic
regions in closely related homologs of gene families
allows quantification of each transcript variant. Finally,
we expect that amplicon based mRNA quantification
can be performed on any deep sequencing instrument
with sufficient data output. However, semiconductor
sequencing is by far the fastest method with three
hours run time and automated read quantification on
the Ion-Torrent system server.
Methods
We have compiled a panel of 917 transcripts derived from
more than 100 human signaling cascades and signaling
networks. These were submitted via web interface for
primer design and probe pool synthesis using proprietary
algorithms (https://www.ampliseq.com/browse.action).
For data analysis, a canonical sequence reference fileand a plug-in for the Ion-Torrent server are provided by
the supplier of the PCR-primer pool (Life Technologies,
Carlsbad, USA).
Samples for validation
We have previously analyzed transcriptional changes during
differentiation from human iPSCs to beating cardiomyo-
cytes at multiple time points [14]. The human cells were of
commercial origin and are not subject to ethical committee
approval. We selected triplicate RNA samples from day 0,
10, 20 and 60 for analysis to confirm transcriptional
changes measured by whole genome microarray analysis
as reference and check for sample integrity according
to the published protocol using the same microarray
platform (HumanHT-12 v4.0 Beadchip, Illumina Inc.,
San Diego, USA).
Amplicon library construction
10 ng of total RNA from each time point and biological
replicate were reverse transcribed to cDNA by poly-A-
priming followed by PCR pre-amplification (15 cycles)
according to the protocol supplied with the Ion AmpliSeq™
RNA Library Kit (Life Technologies, Carlsbad, USA,
Catalog number 4482335). After primer digestion, adapters
and molecular barcodes were ligated to the amplicons
followed by magnetic bead purification. This library
was amplified, purified and stored at -20°C. Amplicon
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Agilent High Sensitivity DNA Kit (Agilent Technologies,
Waldbronn, Germany) according to the manufacturer’s
recommendation.
Semi-conductor sequencing
5 picomoles of each of the 12 samples (4 time points; 3
biological replicates) were barcoded and pooled for
emulsion PCR (ePCR) on Ion Sphere Particles (ISPs)
using the Ion PI Template OT2 200 Kit v3 using the
Ion OneTouch 2 Instrument. Following automated Ion
OneTouch ES enrichment of template-positive ISPs
samples were loaded on an Ion Proton PI chip v2 and
sequenced on an Ion Proton instrument using the Ion PI
sequencing 200 kit v3 (Life Technologies, Carlsbad, USA).
Quantitative RNA sequencing
The same samples as above were sequenced using com-
mercial kits and protocols provided by Life Technologies,
Carlsbad, USA. Briefly, 1.5 μg of total RNA was used to
construct the strand-specific mRNA-Seq libraries using
the SENSE mRNA-Seq Library Prep Kit (Lexogen, Vienna,
Austria). Template preparation and Proton sequencing
was done according to the manufacturer’s instructions
(Life Technologies, Carlsbad, USA).
Read mapping and quantification
Reads were mapped and quantified using the program
TMAP (Torrent Mapping Alignment Program; http://
mendel.iontorrent.com/ion-docs/Technical-Note—TMAP-
Alignment_9012907.html) which is based on different
alignment algorithms [29-32]. The program runs automat-
ically on the Ion-Torrent Server following completion of
sequencing. Reads are mapped to the amplicon sequences
of the panel resulting in fast data processing, quantifica-
tion with concomitant elimination of unspecific amplicons
(typically ~3% of all reads).
Detection of differentially expressed genes
Differentially expressed genes (DEGs) were identified from
microarray data based on linear models using the limma
package in Bionconductor (http://www.bioconductor.org).
We applied three data modelling approaches to AmpliSeq-
RNA with increasing complexities: 1) log2 transformation
(adding an epsilon of 1E-3 to all read counts) 2) voom
(limma package) modelling of mean-variance relationship
and 3) edgeR based on negative binomial distribution [33].
Differential gene expression values determined by three ap-
proaches are virtually identical (R2 > 0.99).
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